Akt Inhibitor XI (FPA-124) is primarily used in research to study the role of the Akt signaling pathway in various cellular processes. It is particularly valuable in cancer research, as it helps to inhibit Akt activity, which is often dysregulated in cancer cells, leading to uncontrolled cell growth and survival. By blocking this pathway, researchers can investigate potential therapeutic strategies for targeting cancers that rely on Akt signaling. Additionally, it is utilized in studies focusing on metabolic regulation, as Akt plays a critical role in glucose metabolism and insulin signaling. This compound is also employed in neurobiology research to explore its effects on neuronal survival and apoptosis, providing insights into neurodegenerative diseases. Its application extends to drug discovery, where it serves as a tool to validate Akt as a target for developing new treatments.